BridgeBio Files New Drug Application for Rare Calcium Disorder Treatment

MT Newswires Live05-12

BridgeBio Pharma (BBIO) said Tuesday that it has submitted a new drug application to the US Food and Drug Administration for encaleret, a potential treatment for autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic condition affecting calcium levels.

The filing is backed by results from a phase 3 trial, where the drug met all main and key secondary goals, the company said.

The study showed 76% of patients on encaleret achieved target serum and urine calcium levels, compared with just 4.4% on standard treatment, it said.

If approved, encaleret could be the first approved therapy specifically indicated for individuals living with ADH1, the company said.

BridgeBio said it is targeting a US launch in early 2027 and plans to file for approval in Europe later this year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment